



RECEIVED
election #9
OCT 11 2002

TECH CENTER 1600/2900

J 10.15.02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF

Nabil Hanna

Group Art Unit: 1642

Application Serial No. 09/822,672

Examiner: L. Helms

Filed: April 2, 2001

Title: COMBINED USE OF ANTI-CYTOKINE ANTIBODIES OR ANTAGONISTS AND ANTI-CD20 FOR THE TREATMENT OF B CELL LYMPHOMA

* * * * *

SUPPLEMENTAL ELECTION RESPONSE

Hon. Commissioner of Patents
Washington, D.C. 20231

Sir:

Applicants confirm their election with traverse of Group X as set forth in Applicant's previous Election. The traversal is for the same reasons set forth in the prior election. As the B cell depleting antibody, Applicants further elect an anti-CD20 antibody. Also, based on this election, Applicants specifically request that Group IX, XI and XIII, be examined together with Group X, as all of these groups treating a type of B cell lymphoma with an anti-IL10 antibody and optionally an anti-CD20 antibody, potentially with other therapeutic agents (chemotherapy).

Therefore, claims 72-73, 76-82 and 83-86 should be examined together with Group X, claims 74-75, as all these groups are so related that the search should be substantially co-extensive.

Respectfully submitted,

PILLSBURY WINTHROP LLP

By: Robin L. Teskin
Robin L. Teskin
Registration No. 35,030

1600 Tysons Boulevard
McLean, Virginia 22102
(703) 905-2000
(703) 905-2500 Facsimile

Date: October 9, 2002